{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:33:49Z","timestamp":1789270429736,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004099","name":"French Ligue Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00520-022-07512-6","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T05:05:58Z","timestamp":1671167158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of adjuvant trastuzumab treatment on fatigue, emotional status and quality of personal and work life of patients with localised breast cancer: results of the \u2018HER-ception\u2019 study"],"prefix":"10.1007","volume":"31","author":[{"given":"Gwenn","family":"Le Gall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Noal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Heutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cherifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Delcambre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"8","key":"7512_CR1","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30(8):1194\u20131220","journal-title":"Ann Oncol"},{"issue":"3","key":"7512_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1470-2045(18)30750-2","volume":"20","author":"ED Saad","year":"2019","unstructured":"Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D et al (2019) Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol 20(3):361\u2013370","journal-title":"Lancet Oncol"},{"issue":"10075","key":"7512_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al (2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA) trial. Lancet Lond Engl 389(10075):1195\u20131205","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"7512_CR4","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol Off J Eur Soc Med Oncol 24(9):2278\u20132284","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"7512_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M et al (2018) Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol Off J Eur Soc Med Oncol 29(3):646\u2013653","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"7512_CR6","first-page":"1025","volume":"37","author":"JE Bower","year":"2018","unstructured":"Bower JE, Wiley J, Petersen L, Irwin M, Cole SW, Ganz PA (2018) Fatigue after breast cancer treatment: Biobehavioral predictors of fatigue trajectories. Health Psychol Off J Div Health Psychol Am Psychol Assoc 37(11):1025\u20131034","journal-title":"Health Psychol Off J Div Health Psychol Am Psychol Assoc"},{"issue":"7","key":"7512_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.19.01726","volume":"38","author":"A Dumas","year":"2020","unstructured":"Dumas A, Vaz Luis I, Bovagnet T, El Mouhebb M, Di Meglio A, Pinto S et al (2020) Impact of breast cancer treatment on employment: results of a multicenter prospective cohort study (CANTO). J Clin Oncol 38(7):734\u2013743","journal-title":"J Clin Oncol"},{"issue":"12","key":"7512_CR8","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/cancers11121896","volume":"11","author":"F Joly","year":"2019","unstructured":"Joly F, Lange M, Dos Santos M, Vaz-Luis I, Di Meglio A (2019) Long-term fatigue and cognitive disorders in breast cancer survivors. Cancers 11(12):1896","journal-title":"Cancers"},{"key":"7512_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12955-020-01591-x","volume":"18","author":"P Mokhtari-Hessari","year":"2020","unstructured":"Mokhtari-Hessari P, Montazeri A (2020) Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes 18:338","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"7512_CR10","first-page":"2164","volume":"90","author":"P Lueboonthavatchai","year":"2007","unstructured":"Lueboonthavatchai P (2007) Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thail Chotmaihet Thangphaet 90(10):2164\u20132174","journal-title":"J Med Assoc Thail Chotmaihet Thangphaet"},{"issue":"6","key":"7512_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"7512_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","volume":"52","author":"I Bjelland","year":"2002","unstructured":"Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52(2):69\u201377","journal-title":"J Psychosom Res"},{"issue":"2","key":"7512_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag 13(2):63\u201374","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"7512_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/cer.14.76","volume":"4","author":"J Nguyen","year":"2015","unstructured":"Nguyen J, Popovic M, Chow E, Cella D, Beaumont JL, Chu D et al (2015) EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res 4(2):157\u2013166","journal-title":"J Comp Eff Res"},{"issue":"3","key":"7512_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol Off J Am Soc Clin Oncol 11(3):570\u2013579","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15_suppl","key":"7512_CR16","doi-asserted-by":"publisher","first-page":"e17753","DOI":"10.1200\/jco.2015.33.15_suppl.e17753","volume":"33","author":"EA Hahn","year":"2015","unstructured":"Hahn EA, Segawa E, Kaiser K, Cella D, Smith BD (2015) Validation of the functional assessment of cancer therapy-breast (FACT-B) quality of life instrument. J Clin Oncol 33(15_suppl):e17753\u2013e17753","journal-title":"J Clin Oncol"},{"issue":"3","key":"7512_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","volume":"15","author":"MJ Brady","year":"1997","unstructured":"Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR et al (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol Off J Am Soc Clin Oncol 15(3):974\u2013986","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"7512_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1037\/0022-006X.69.6.1026","volume":"69","author":"AW Evers","year":"2001","unstructured":"Evers AW, Kraaimaat FW, van Lankveld W, Jongen PJ, Jacobs JW, Bijlsma JW (2001) Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol 69(6):1026\u20131036","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"7512_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ygyno.2014.10.013","volume":"136","author":"XS Wang","year":"2015","unstructured":"Wang XS, Woodruff JF (2015) Cancer-related and treatment-related fatigue. Gynecol Oncol 136(3):446\u2013452","journal-title":"Gynecol Oncol"},{"issue":"3","key":"7512_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000509410","volume":"16","author":"L Kowalczyk","year":"2021","unstructured":"Kowalczyk L, Deutschmann C, Crevenna R, Konrad S, Singer CF, Farr A (2021) Radiotherapy-induced fatigue in breast cancer patients. Breast Care 16(3):236\u2013242","journal-title":"Breast Care"},{"issue":"6","key":"7512_CR21","first-page":"916929","volume":"13","author":"H Mohandas","year":"2017","unstructured":"Mohandas H, Jaganathan SK, Mani M, Ayyar M, Rohini Thevi GV (2017) Cancer-related fatigue treatment\u202f: an overview. J Cancer Res Ther 13(6):916929","journal-title":"J Cancer Res Ther"},{"key":"7512_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139\u2013144","journal-title":"J Clin Oncol"},{"issue":"7","key":"7512_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jama.2009.187","volume":"301","author":"AGEM de Boer","year":"2009","unstructured":"de Boer AGEM, Taskila T, Ojaj\u00e4rvi A, van Dijk FJH, Verbeek JHAM (2009) Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 301(7):753\u2013762","journal-title":"JAMA"},{"issue":"1","key":"7512_CR24","first-page":"13","volume":"33","author":"J Endicott","year":"1997","unstructured":"Endicott J, Nee J (1997) Endicott work productivity scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 33(1):13\u201316","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"7512_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/01.MLR.0000062551.76504.A9","volume":"41","author":"D Lerner","year":"2003","unstructured":"Lerner D, Amick BC, Lee J, Rooney T, Rogers WH, Chang H, Berndt ER (2003) Relationship of employee-reported work limitations to work productivity. Med Care 41(5):649\u2013659","journal-title":"Med Care"},{"issue":"5","key":"7512_CR26","doi-asserted-by":"publisher","first-page":"R177","DOI":"10.1186\/ar3141","volume":"12","author":"W Zhang","year":"2010","unstructured":"Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis H, AH, (2010) Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis. Arthritis Res Ther 12(5):R177","journal-title":"Arthritis Res Ther"},{"key":"7512_CR27","unstructured":"La vie cinq ans apr\u00e8s un diagnostic de cancer - Rapport - Ref\u202f: ETUDVIEK518 [Internet]. [cited 2022 Jul 4]. Available from: https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/La-vie-cinq-ans-apres-un-diagnostic-de-cancer-Rapport"},{"issue":"8","key":"7512_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.6004\/jnccn.2010.0067","volume":"8","author":"AM Berger","year":"2010","unstructured":"Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D et al (2010) NCCN clinical practice guidelines cancer-related fatigue. J Natl Compr Cancer Netw JNCCN 8(8):904\u2013931","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"2","key":"7512_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134\u2013141","journal-title":"N Engl J Med"},{"issue":"22","key":"7512_CR30","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/JCO.19.00066","volume":"37","author":"SM Tolaney","year":"2019","unstructured":"Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L et al (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2\u2013positive breast cancer. J Clin Oncol 37(22):1868\u20131875","journal-title":"J Clin Oncol"},{"issue":"2","key":"7512_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122\u2013131","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07512-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T09:21:26Z","timestamp":1674033686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07512-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["7512"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07512-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (N\u00b0EudraCT: 2011\u2013003031-55) received ethical approval from the <i>Comit\u00e9 de Protection des Personnes Nord-Ouest III<\/i> in April 2011 and from the French Health Authority in July 2011. All patients were invited to participate by their medical oncologists, who provided them with an information leaflet. All patients gave their informed consent before any study-related assessment began. All procedures performed in the present study were in accordance with national and international ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"F. Joly: consulting for Roche, GSK, Astra Zeneca, Clovis, MSD, Ipsen, Janssen, Astellas, Pfizer, Sanofi, BMS, Bayer. All other authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"38"}}